The Enduring Legacy of Mitragyna speciosa: An In-Depth Historical Analysis of Kratom

Abstract

Mitragyna speciosa, commonly known as Kratom, is a tropical tree with a history spanning centuries, evolving from a culturally integrated traditional remedy in Southeast Asia to a globally recognized substance of interest and controversy. This research paper provides an in-depth historical analysis, tracing Kratom’s botanical origins, its formal scientific discovery, and the evolution of its pharmacological understanding. It examines the deep ethnobotanical roots and diverse traditional uses across Thailand, Malaysia, and Indonesia, contrasting these with its relatively recent and rapid global dissemination, largely driven by modern public health challenges such as the opioid crisis. The report further explores the complex and often contradictory regulatory responses in both native and Western countries, highlighting how economic factors, scientific ambiguity, and public perception have shaped its legal status. Finally, it details the historical and contemporary accounts of Kratom’s adverse effects, addiction potential, and withdrawal syndrome, emphasizing the amplified risks associated with an unregulated market and the critical ongoing need for comprehensive scientific research to inform future policy and public health strategies.

1. Introduction

Mitragyna speciosa, universally recognized as Kratom, stands as a compelling botanical specimen, a tropical tree indigenous to the lush landscapes of Southeast Asia, including Thailand, Malaysia, Myanmar, Indonesia, and Papua New Guinea. Belonging to the Rubiaceae family, which also includes the ubiquitous coffee tree, Kratom can attain impressive dimensions, reaching heights of up to 50 feet with a canopy spread exceeding 15 feet. The leaves of this tree are notable for their rich array of bioactive alkaloids, with mitragynine and 7-hydroxymitragynine identified as the primary compounds responsible for its distinctive psychoactive properties. The trajectory of Kratom’s influence has transformed dramatically over time, transitioning from a localized traditional remedy, deeply woven into the fabric of indigenous cultures, to a global phenomenon that now commands the attention of consumers, researchers, and regulatory bodies worldwide.

The purpose of this paper is to offer a comprehensive historical examination of Kratom. This analysis will meticulously trace its journey from its ancient ethnobotanical roots and traditional applications to its formal scientific recognition, the evolving understanding of its pharmacology, and its subsequent global dissemination. Furthermore, the discussion will encompass the intricate and often contentious regulatory landscape that has emerged in response to its increasing prevalence. A central theme in this historical narrative is the fundamental divergence in how Kratom is perceived and utilized across different geographies. In its native lands, it has maintained a long-standing, culturally integrated role, serving both practical and ceremonial purposes for centuries. In stark contrast, its relatively recent emergence in Western nations, largely beginning in the early 2000s and accelerating in the 2010s , has been marked by significant controversy and a focus on its psychoactive properties and potential for dependence. This stark contrast in perception and application forms a central tension throughout Kratom’s history, highlighting its complex identity.

The classification of Kratom as a “natural” substance, owing to its botanical origin, further contributes to a nuanced and occasionally misinformed public understanding, particularly within Western societies. While the plant’s natural provenance is undeniable, as it is derived directly from a tropical tree , regulatory bodies such as the U.S. Food and Drug Administration (FDA) have issued warnings regarding its “potential for addiction, abuse, and dependence” and the risk of “serious adverse events”. The observation that a substance is not inherently safer simply because it is natural challenges a common misconception that has influenced its adoption in new markets. This situation underscores a broader societal challenge in distinguishing between traditional herbal remedies, which often have a context of long-term local knowledge, and unregulated psychoactive substances entering new consumer environments. The historical narrative of Kratom thus reveals a complex interplay between traditional wisdom, scientific discovery, and evolving societal perceptions.

2. Botanical Origins and Early Ethnobotanical History

The foundational history of Kratom is rooted in its botanical classification and its deep cultural integration within the indigenous communities of Southeast Asia.

2.1. Classification and Native Habitat

Kratom, formally identified as Mitragyna speciosa (korth), is a tropical tree classified within the Rubiaceae family, which notably includes the coffee tree. The genus name,

Mitragyna, is derived from the distinctive resemblance of its leaves to a bishop’s ceremonial hat, known as a miter. This evergreen tree is indigenous to the warm, humid climates and fertile soils characteristic of Southeast Asia, flourishing particularly in Thailand, Malaysia, Indonesia (including Sumatra, Borneo, Sulawesi, and Kalimantan), Myanmar, and Papua New Guinea. Related species within the

Mitragyna genus have a broader geographical distribution, extending as far as India and South Africa.

2.2. Earliest Documented Mentions and Formal Discovery

The earliest references to Kratom’s use in Western medical literature date back to 1836, where its application as an opium substitute in Malaysia was noted. The formal botanical description of

Mitragyna speciosa was provided in 1839 by the Dutch colonial botanist Pieter Willem Korthals, who initially named the species Stephegyne speciosa. The plant subsequently underwent several reclassifications before George Darby Haviland established its final name and classification in 1859.

While 1836 marks the first Western documentation, the traditional use of Kratom in Southeast Asia is believed to extend much further into the past, potentially to prehistoric times. This earlier use is suggested by enduring oral traditions and archaeological evidence. For instance, Dutch colonizers arriving in Southeast Asia in the 17th century documented local inhabitants chewing the leaves to enhance productivity and alleviate pain. This historical context highlights that the plant’s utility was recognized and integrated into local cultures long before its formal scientific classification by Western botanists.

2.3. Traditional Uses and Cultural Significance in Southeast Asia

For many centuries, Kratom has been an integral component of traditional medicine and cultural practices throughout Southeast Asia. The initial widespread adoption of Kratom was largely driven by its utility in mitigating the demanding conditions of manual labor and addressing common health ailments, rather than a primary pursuit of recreational effects. Its primary traditional application was as a stimulant for laborers and farmers in Thailand and Malaysia, assisting them in overcoming the arduousness of hard work, boosting energy levels, and alleviating muscle strains. Workers commonly chewed fresh leaves to combat fatigue and enhance productivity and endurance during long hours in the fields. In certain Thai communities, the saying “Strong as a kratom chewer” emerged, symbolizing endurance and resilience, which further underscores the plant’s role in supporting strenuous physical activity.

Beyond its stimulant properties, Kratom held significant value in traditional medicine. It was historically employed in Southeast Asia, particularly in Thailand and Malaysia, as a substitute for opium when the latter was unavailable, and to manage the symptoms of opioid withdrawal. This pragmatic application in managing addiction, especially in contexts where conventional treatments were scarce, highlights its functional importance. Furthermore, Kratom was widely used to alleviate musculoskeletal pain, muscle aches, and chronic pain. Traditional healers and communities also utilized Kratom for a diverse range of ailments, including coughs, diarrhea, intestinal infections (serving as deworming agents), diabetes, fever, and as a poultice for wounds.

The use of Kratom was deeply embedded in the cultural and social fabric of these communities. It played a role in social rituals, such as being offered as a “snack to receive guests” in Thailand or as a sign of hospitality in Malaysia. Communal consumption was often part of rituals aimed at strengthening community bonds. In some animistic belief systems, Kratom was revered as a sacred plant, believed to be a gift from spirits. Shamans and spiritual leaders reportedly used it to achieve altered states of consciousness, facilitating communication with ancestral and nature spirits. In Malay culture, Kratom was associated with the concept of “semangat,” referring to the life force or soul, with the belief that its consumption could enhance an individual’s resilience to life’s challenges. The cultivation and harvesting of Kratom were frequently accompanied by specific rituals and beliefs, such as the practice of harvesting leaves in the early morning. The herb itself is notably bitter, and traditionally, it was often combined with a sweetener to improve palatability. It is important to note that, prior to the 2000s, there is no scientific documentation of traditional uses of Kratom preparations outside of Asia. This indicates that the plant’s deep integration into local cultures meant its knowledge was largely self-contained, and its eventual global spread represented a disruptive phenomenon, leading to a lack of established understanding and regulatory frameworks in new contexts.

Even in traditional contexts, an implicit understanding of Kratom’s biphasic, dose-dependent effects was evident. While not articulated in pharmacological terms, descriptions of Kratom being used as a “stimulant” for work at lower doses and for “pain relief” or “calming effects” at higher doses demonstrate an experiential recognition of its varied effects based on quantity. The phrase “Strong as a kratom chewer” for endurance, contrasted with its use for “relaxation and social rituals” , further supports this observation. This early, empirical understanding of dose-dependency provided a practical foundation for later scientific investigations into its complex pharmacology.

3. Traditional Cultivation, Harvesting, and Preparation MethodsThe historical interaction of indigenous communities with Kratom involved specific practices for its cultivation, harvesting, and preparation, reflecting a deep, empirical understanding of the plant’s properties.

3.1. Cultivation Practices

Kratom trees thrive in the warm and humid climates of Southeast Asia, requiring a specific combination of abundant sunlight, consistent rainfall, and rich, fertile soil. These trees are frequently found flourishing at the edges of rivers and in areas characterized by fertile alluvial soils rich in organic matter. Traditional cultivation practices involve meticulous care, with farmers typically propagating Kratom either through seeds or by taking cuttings from mature trees. Once planted, the trees require several years to reach their full maturity, during which period they are carefully nurtured with proper irrigation, organic fertilizers, and protection from pests.

A significant aspect of traditional Kratom cultivation is the adherence to sustainable and organic farming practices. This includes the deliberate avoidance of harmful pesticides and synthetic fertilizers, which is crucial for protecting the soil quality and local water systems. Furthermore, the practice of agroforestry, where Kratom is grown alongside other crops or trees, is common. This approach not only promotes biodiversity within the agricultural system but also provides direct benefits to local communities. The cultivation of Kratom has historically served as an alternative, sustainable income opportunity for many communities, thereby reducing the reliance on more destructive land use practices such as slash-and-burn farming.

3.2. Harvesting Techniques

The timing and method of harvesting Kratom leaves are critical to ensuring the potency of the plant’s alkaloids. Leaves are typically selected when they are mature and have developed the highest concentration of these active compounds. Skilled harvesters, often local farmers, employ traditional methods, either hand-picking the leaves or carefully using tools to pluck them. They prioritize leaves with a vibrant green color, while avoiding those that appear damaged or diseased. Notably, the leaf veins are generally not included in the production of leaf powder, suggesting an early understanding of the distribution of active compounds within the plant.

Kratom producers have, over centuries of trial and error, established highly accurate harvesting schedules to optimize the yield and alkaloid profile of the leaves. For example, in Kapuas Hulu, Indonesia, harvesting commences when the plants are approximately 6 months old and about 1 meter tall. During this initial harvest, older leaves are picked, while 4-6 young leaves are intentionally left on the plants to ensure continued growth. The first harvest typically yields between 0.5 to 0.75 kg per tree. Subsequent harvests occur every 1.5 to 3 months, depending on the condition of the plants, with productivity often improving by approximately 30% in the second crop and continuing to increase thereafter. For taller branches, traditional harvesters may use bamboo or rope to facilitate easier access and collection. These practices, honed over generations, demonstrate an empirical optimization of the plant’s biochemistry long before formal scientific analysis.

3.3. Preparation Methods

Traditionally, fresh or dried Kratom leaves were primarily consumed by chewing or by brewing them into teas. Smoking the leaves was a less common method of consumption. When chewing, traditional “kratom eaters” would typically masticate one to three fresh leaves at a time to achieve desired effects such as vigor and euphoria. It was common practice to remove the veins from the leaves before chewing, and sometimes salt was added, reportedly to prevent constipation. Only the masticated material was swallowed, often followed by a drink of warm water, coffee, tea, or palm sugar syrup. Regular users might engage in this practice anywhere from 3 to 10 times a day.

For tea preparation, lemon juice was frequently added, a practice that likely facilitated the extraction of the plant’s alkaloids due to the acidic environment. Sugar or honey might then be incorporated to mask the herb’s inherently bitter taste. The precision in these traditional methods, such as harvesting mature leaves for higher alkaloid concentration or adding lemon juice to tea, indicates an intuitive ethnobotanical understanding of chemical solubility and bioavailability. This suggests that traditional users, through generations of observation and practice, effectively conducted their own form of “pharmacological studies.”

A notable development in regional consumption patterns, particularly among youth in Southeast Asia and Thailand, was the emergence of the “4×100” cocktail around the 2010s. This concoction typically combines Kratom leaves with cough syrup (often containing codeine), Coca-Cola, and ice. The appearance of this mixed beverage represents an early historical instance of Kratom being combined with other psychoactive substances, moving beyond the plant’s singular use. This development foreshadowed later concerns about poly-drug use in Western contexts. The “4×100” cocktail was generally viewed more negatively than traditional Kratom use but less negatively than heroin use, indicating a societal recognition of altered risk profiles associated with such combinations. This regional precedent highlights that the potential for misuse and dangerous combinations is not exclusively a Western phenomenon but can evolve from changing consumption patterns within traditional regions.

In Western countries, Kratom has become available in a wider variety of processed forms, including whole or crushed dried leaves, fine powder, concentrated extracts, encapsulated powder, and extract resin “pies” (40-gram pellets made from reduced extract). The availability of seeds and even whole trees through some online vendors also suggests the possibility of domestic cultivation outside its native habitat.

4. Evolution of Scientific Understanding and Pharmacological Insights

The scientific journey of Kratom has progressed from the initial isolation of its chemical components to a more nuanced understanding of its complex pharmacology, influencing perceptions of its effects over time.

4.1. Early Chemical Isolation and Characterization

The primary active alkaloid in Kratom, mitragynine, was first isolated from its leaves in 1921 by Ellen Field, a medicinal chemist affiliated with the University of Edinburgh. Decades later, in 1964, its chemical structure was precisely characterized using X-ray crystallography by a research group led by G.A. Jeffrey at the University of Pittsburgh. Concurrently, beginning in 1961, Joseph Shellard and Arnold Beckett at Chelsea College, London, along with their PhD students David Phillipson and Albert Tackie, embarked on extensive examinations of the chemical structures of both known and novel alkaloids found in

Mitragyna speciosa and other Mitragyna species. Phillipson’s work with Shellard notably resulted in the isolation of 16 distinct alkaloids from

M. speciosa and four other Mitragyna species.

Kratom leaves are known to contain at least 37 different alkaloids. Among these, mitragynine and 7-hydroxymitragynine (7-OHMG) are recognized as the two primary active components. Mitragynine is the most prevalent alkaloid, constituting approximately 2% of Kratom preparations by mass and up to 66% of the total alkaloid content. In contrast, 7-OHMG, an oxidized analog of mitragynine, is present in much smaller quantities, generally less than 0.02%. When ingested, mitragynine is metabolized in the body, breaking down into 7-hydroxymitragynine.

4.2. Historical Perceptions of Effects

Early scientific investigations into whole Kratom extracts provided initial insights into its effects. These studies indicated that the extract exerted a stimulant effect in both humans and animals, described as “comparable to cocaine,” but only a “weak analgesic effect equivalent in potency to that of codeine”. Historically, users also reported experiencing a “high” after ingesting Kratom, which contributed to its recreational use.

The use of Kratom in Southeast Asia has been documented for at least 150 years, dating back to 1836. Throughout this period, traditional accounts consistently described a stimulant effect when fresh leaves were chewed, typically for enhancing performance during hard labor. Conversely, an analgesic and relaxing effect was observed when the leaves were brewed into a tea. This historical understanding aligns with modern observations of dose-dependent effects: at low doses, typically 1-5 grams, Kratom produces stimulant effects, with users reporting increased alertness, physical energy, talkativeness, and sociable behavior. At higher doses, generally 5-15 grams, opioid-like effects become predominant, accompanied by sedative and euphoric sensations. The onset of these effects typically occurs within 5 to 10 minutes after ingestion and can last for 2 to 5 hours.

4.3. Modern Pharmacological Discoveries

Modern pharmacological studies have significantly advanced the understanding of Kratom’s mechanisms of action. These studies reveal that mitragynine and 7-hydroxymitragynine primarily exert their effects through mu-opioid receptor agonist activity. Beyond this, they also interact with delta opioid receptors, as well as alpha 2 adrenergic and 5-HT2A receptors. Animal studies have even suggested that Kratom may be more potent than morphine in certain contexts.

A particularly significant discovery in modern pharmacology is that while mitragynine and 7-hydroxymitragynine act as partial agonists for mu-opioid receptors, their activity notably lacks beta-arrestin 2 recruitment. This is a crucial distinction, as beta-arrestin signaling has been associated with many of the undesirable effects of classical opioid receptor activation, including constipation, respiratory depression, and dependence. This unique pharmacological profile is hypothesized to explain Kratom’s anecdotal ability to induce less respiratory depression and potentially reduced euphoric effects compared to widely abused opioids like heroin or morphine. This progression in scientific understanding, moving from simply identifying compounds to elucidating their precise mechanisms of action at a molecular level, is critical for explaining the observed dose-dependent effects and the nuanced differences from classical opioids.

Historically, there was pharmaceutical interest in Kratom’s alkaloids. In the 1960s, the pharmacy company Smith Kline French (which later merged into GlaxoSmithKline) explored the possibility of developing mitragynine as a painkiller to replace morphine. However, this development was ultimately halted because toxicity tests revealed that mitragynine was toxic to beagle dogs. This early commercial interest and subsequent abandonment illustrate the historical challenges inherent in translating traditional remedies into modern pharmaceuticals. It demonstrates that while Kratom’s therapeutic potential was recognized early on, the complexities of its pharmacology and safety profile, even for isolated compounds, presented significant hurdles for conventional drug development, a situation that continues to inform current debates about its safety and efficacy, particularly given the lack of FDA approval for any medical use.

Modern research also highlights that Kratom’s effects can vary widely depending on several factors, including the amount taken, the product’s potency (concentration and strength), its specific formulation, the method of ingestion, the presence of other drugs in a person’s system, and individual physiological factors. The concentration and combination of specific Kratom compounds within a product also significantly influence the resulting effects. It is important to acknowledge that scientific research on Kratom is relatively nascent compared to studies on more widely used drugs. Consequently, much remains unknown about its various chemical compounds, the full spectrum of its short- and long-term health impacts, and its potential therapeutic applications.

5. The Global Spread and Modern Landscape of Kratom Use

The trajectory of Kratom’s use shifted dramatically as it moved beyond its native Southeast Asian regions, becoming a globally recognized, albeit controversial, substance.

5.1. Introduction to Western Countries

While Kratom’s traditional use in Southeast Asia spans centuries, its documented presence and widespread adoption in the United States are relatively recent phenomena, with initial cases emerging in the early 2000s. Although botanists like Pieter Willem Korthals introduced Kratom to the Western Hemisphere in the 19th century , its significant popularization outside of Asia is a distinctly modern development. By 2015, Kratom products were readily available in outlets such as head shops and through online vendors in the U.S.. The prevalence of its use subsequently experienced a rapid increase between 2011 and 2017. By 2020, estimates suggested that approximately 15 million people in the U.S. were using Kratom. Similar increases in sales have also been observed across Europe and North America.

5.2. Drivers of Modern Popularity

A primary impetus for Kratom’s burgeoning popularity in Western countries has been its perceived utility for self-treatment of various conditions. This is particularly evident in its use for managing chronic pain and alleviating opioid withdrawal symptoms. Many individuals have turned to Kratom as an alternative to conventional pain medications, seeking a “natural” solution for persistent pain conditions. The opioid epidemic in Western countries, especially the United States, significantly catalyzed Kratom’s introduction and widespread adoption as a perceived natural alternative. The rapid increase in Kratom use in the U.S. between 2011 and 2017 directly coincided with a period of heightened awareness and increased regulation of prescription opioids. The explicit linking of Kratom’s growth to the time when “opioids began to become more regulated in the 2010s” points to a direct causal relationship. This suggests that a public health crisis, namely the opioid epidemic, created a substantial demand for alternatives, which Kratom, despite its unregulated status, began to fulfill due to its perceived opioid-like effects and accessibility.

Beyond pain and withdrawal, Kratom is also used to address symptoms of mental health conditions such as anxiety and depression. Furthermore, some users seek its stimulant effects for increased energy, alertness, talkativeness, and sociability, or for enhanced productivity and focus in academic or professional settings. A 2020 survey indicated that over 50% of users reported employing Kratom for its energy-boosting effects. Another survey of 2,798 users found that 41% utilized Kratom to cease or reduce prescription or illicit opioid use, with 411 individuals attributing over a year of continuous opioid abstinence to Kratom consumption. The perception that Kratom offers comparable pain relief to opioids but with a potentially lower risk of addiction has also contributed to its rising popularity.

5.3. Evolution of Kratom Products and Availability

The modern Kratom market has seen a diversification of product forms beyond the traditional raw leaves. Consumers can now find Kratom in various preparations, including whole or crushed leaves, fine powder, concentrated extracts, encapsulated powder, and even extract resin “pies”. The availability of Kratom seeds and even whole trees through online vendors suggests the growing possibility of domestic cultivation in non-native regions.

A notable development in the market is the significant growth of Kratom-infused beverages, with products such as seltzers and shots now emerging. Of particular concern is the marketing of products containing highly concentrated forms of 7-hydroxymitragynine. This represents a significant shift from the consumption of the whole plant, where 7-OHMG is naturally present only in trace amounts. The critical detail is that 7-OHMG has been identified as being “14-22 times more potent than morphine” , and some commercially available Kratom products have been found to contain “notably elevated concentrations of 7-hydroxymitragynine” compared to natural leaves. This innovation in product formulation introduces new and potentially more dangerous consumption patterns, as it bypasses the natural balance of alkaloids found in the plant, thereby increasing the risk of dependence and addiction. This creates a new category of risk that was not encountered in traditional use patterns and presents a considerable challenge for regulators attempting to classify “Kratom” as a singular entity.

5.4. Shifting Perceptions and Controversies

Kratom’s transition from a localized traditional remedy to a globally debated substance is marked by a complex interplay of shifting perceptions. While proponents advocate for its therapeutic potential in pain management and opioid withdrawal, critics emphasize the notable absence of rigorous, large-scale clinical studies and the inherent potential for misuse.

A significant factor influencing its modern adoption is the belief that Kratom is a safe, herbal alternative. This perception, however, is often misleading, as it can lead users to underestimate the substance’s pharmacological potency and its potential for addiction. The rapid global dissemination of Kratom into Western markets occurred in an information vacuum regarding its long-term effects and safety. The repeated assertion that “there is no scientific information on traditional uses of Kratom preparations before the 2000s outside of Asia” is critical. This absence of pre-existing scientific or medical understanding meant that when Kratom entered Western markets, there was little established knowledge of its effects, risks, or traditional context. This vacuum allowed for the proliferation of anecdotal claims and marketing strategies that frequently oversimplified its safety. The lack of comprehensive regulation and clear labeling further exacerbated this issue, contributing to a “misleading safety” perception. This situation demonstrates how the absence of established scientific and regulatory frameworks can create an environment conducive to misinformation and underestimated risks as a traditional substance transitions into a new global context.

The U.S. Food and Drug Administration (FDA) has taken a firm stance, classifying Kratom as an “unapproved new dietary ingredient” and issuing warnings to consumers to avoid its use due to documented risks of serious adverse events, including liver toxicity, seizures, and substance use disorder. This highlights the ongoing scientific and regulatory debate surrounding Kratom’s place in modern society.

6. Historical and Contemporary Regulatory Responses

The regulatory history of Kratom is complex and often contradictory, reflecting a global debate shaped by traditional use, emerging scientific understanding, economic interests, and public health concerns

6.1. Regulatory History in Southeast Asia

Thailand: Thailand’s regulatory approach to Kratom has undergone significant shifts. The country first implemented restrictions on Kratom use for medical purposes in 1943 with the Kratom Plant Act B.E. 2486. This initial restriction was largely a response to Kratom’s surge in popularity as an alternative when the cost of opium escalated due to stringent laws aimed at curbing the illicit opium market. This historical context suggests that the early prohibition was not solely a public health measure but also an economic and social response to the dynamics of other illicit drug markets, mirroring historical “opium wars” where broader interests influenced drug policy. The 1943 act made planting new Kratom trees illegal and mandated the destruction of existing ones. In 1979, Kratom was further reclassified as a Category 5 narcotic under the Narcotics Act B.E. 2522, effectively imposing a comprehensive prohibition on its consumption, cultivation, trade, and distribution.

However, Thailand’s policy began to evolve. In 2019, the government legalized the production, possession, and use of both cannabis and Kratom for medical purposes. This shift culminated in a significant decriminalization, effective August 24, 2021, when Kratom was entirely removed from the list of controlled narcotics. This legislative change permits its consumption, production, disposal, import, export, and possession for any purpose and in any quantity or form. This recent decriminalization reflects a policy shift towards acknowledging traditional cultural practices and the plant’s economic value, moving away from Western-influenced prohibition models. The decision was explicitly based on its role in “traditional Thai cultural norms” and its absence from the UN Single Convention on Narcotic Drugs. This move is part of a broader strategic push for legal reform designed to align the law with current societal conditions and expectations, ensuring that regulations do not unduly “obstruct livelihoods or occupations”. Despite decriminalization, draft legislation is anticipated to regulate its sale and use, including licensing requirements for industrial use, prohibitions on sales to minors and pregnant/nursing women, and clarifications on labeling and advertising.

Malaysia: In Malaysia, Kratom has been legally banned, classified as a poison under the Poison Act of 1952. Despite this prohibition, the native trees and traditional tea decoctions remain “abundantly available” throughout the country, indicating challenges in enforcement and the persistence of traditional use patterns.

Indonesia: Indonesia holds a unique position as the world’s largest producer and exporter of Kratom, with its cultivation providing substantial economic benefits to numerous rural communities. This economic reliance creates significant resistance to outright bans. However, Kratom’s legal status within Indonesia is complex and subject to ongoing evolution. Since 2013, the United Nations Office on Drugs and Crime (UNODC) has classified Kratom as a New Psychoactive Substance (NPS). The National Narcotics Agency (BNN) in Indonesia has actively advocated for a total ban, classifying Kratom as a Class 1 narcotic, with a policy for a complete prohibition slated to be effective as of 2022. Farmers have been advised to transition to alternative crops. The BNN has justified its stance by claiming Kratom contains opioids and is highly addictive, even asserting it is “more dangerous than morphine”. This push for prohibition has already led to a decline in Kratom cultivation. Despite these governmental efforts, Kratom currently remains legal in Indonesia and is deeply rooted in its culture, allowing for cultivation and consumption, though its use in traditional medicines and health supplements was prohibited by a circular letter in 2016. An ongoing debate persists regarding legal certainty and protection for farmers reliant on Kratom cultivation.

6.2. Regulatory Landscape in Western Countries

United States: At the federal level, Kratom is not currently regulated under the Controlled Substances Act (CSA) and does not appear on its list of controlled substances. However, the U.S. Drug Enforcement Agency (DEA) has formally designated Kratom as a “Drug and Chemical of Concern”. In August 2016, the DEA announced its intention to temporarily classify Kratom as a Schedule I substance, citing concerns about its potential for abuse and public safety risks. This proposal, however, met with significant public backlash, including demonstrations, petitions, and congressional opposition, leading the DEA to withdraw its notice of intent in October 2016. Since then, the FDA has made multiple attempts to recommend that Kratom’s active compounds, mitragynine and 7-hydroxymitragynine, be scheduled as Schedule I. These recommendations have consistently been rejected by the DEA, the Department of Health and Human Services (HHS), and the Expert Committee on Drug Dependence (ECDD) for the U.N. Commission on Narcotic Drugs.

The fragmented and inconsistent regulatory landscape, particularly in the U.S., is a direct consequence of ongoing scientific uncertainty, strong public advocacy, and significant economic interests. The repeated rejections of the FDA’s Schedule I recommendations, despite the FDA’s strong warnings , highlight a fundamental disagreement at the federal level regarding Kratom’s classification. This, combined with the “significant public backlash” against the DEA’s 2016 scheduling attempt and the fact that “state markets continue to grow due to public support for its use” , demonstrates a powerful interplay of factors beyond pure scientific consensus. The existence of a “growing, billion-dollar industry” further complicates the regulatory picture. This “patchwork” of regulations , where 22 states and the District of Columbia regulate Kratom in some capacity (ranging from controlling psychoactive components to regulating products with age restrictions, marketing limitations, quality standards, and taxation) , is a direct outcome of these conflicting pressures. The lack of definitive scientific consensus allows economic and advocacy forces to shape policy, leading to inconsistent legal statuses that create confusion and challenges for both consumers and regulators. Despite the FDA’s active efforts to limit Kratom availability through warnings and actions against companies selling unapproved products, the sheer size of the market and public support have made it difficult for the FDA to restrict its widespread availability.

Other International Jurisdictions: Kratom and its compounds are not currently under international control by the World Health Organization (WHO). However, various national controls are in place across several European countries, including the United Kingdom (where it is promoted as an “herbal speedball”), Finland, Lithuania, Denmark, Poland, and Sweden, as well as in Australia.

6.3. Factors Influencing Regulatory Debates

The ongoing regulatory debates surrounding Kratom are influenced by a confluence of factors. The most prominent is the inherent conflict between its long history of traditional use as a remedy and modern public health concerns regarding its psychoactive properties, potential for addiction, and documented adverse effects. In producer countries like Indonesia, the significant economic impact of Kratom cultivation, which serves as a crucial source of livelihood for farmers, creates substantial economic resistance to bans.

Furthermore, the relatively nascent stage of scientific research on Kratom means that much remains unknown about its long-term health impacts and potential therapeutic uses. This scientific uncertainty contributes significantly to regulatory ambiguity and fuels ongoing debate. Advocates for Kratom often highlight its perceived benefits in pain management and opioid withdrawal, which garners public and political support for its continued legality. Compounding these challenges are concerns about product purity, including contamination with harmful substances like salmonella, heavy metals, or adulteration with other psychoactive substances (e.g., tramadol in “krypton,” fentanyl). These issues complicate regulatory efforts and pose serious safety risks to consumers.

7. Historical Accounts of Adverse Effects, Addiction, and Withdrawal

The historical narrative of Kratom is not solely one of traditional utility and scientific discovery; it also encompasses a documented history of adverse effects, the recognition of its addiction potential, and the characterization of a distinct withdrawal syndrome.

7.1. Early Observations of Dependence and Withdrawal

Kratom consumption has been observed to lead to addiction. A study of Thai Kratom users revealed patterns of daily consumption ranging from 3 to 30 years, with an average duration of 18.6 years, indicating a long history of sustained use and dependence in native regions. Despite its traditional medical applications, Kratom dependence has been recognized and documented in Southeast Asia for a considerable period. It is noteworthy that, unlike addiction to opium or heroin, Kratom addiction in rural communities was not historically associated with a significant social stigma if its use was perceived to support a family’s livelihood. In contemporary Western contexts, the U.S. FDA has explicitly stated its belief that Kratom may “expose users to the risks of addiction, abuse, and dependence” due to its interaction with opioid receptors in the brain.

7.2. Documented Acute and Chronic Adverse Effects

The adverse effects associated with Kratom use can manifest acutely or chronically. Acute side effects commonly reported include nausea, itching, sweating, dry mouth, constipation, increased urination, and loss of appetite. At higher doses, users may experience more pronounced nausea, vomiting, and indigestion. Other acute symptoms include dizziness, drowsiness, agitation, tachycardia (rapid heart rate), and confusion.

Long-term use of Kratom has been linked to a range of chronic adverse effects. These include anorexia, weight loss, insomnia, darkening of the skin (hyperpigmentation, particularly over the face and cheeks), persistent dry mouth, frequent urination, and chronic constipation. Chronic users may also experience cognitive impairments, psychosis, and liver damage. Additionally, hormonal imbalances, such as reduced testosterone levels in men, have been reported.

More severe adverse effects, though rare, have been documented. These encompass mental and neurological symptoms like confusion, tremors, seizures, paranoia, and hallucinations. Cardiovascular and respiratory problems, including high blood pressure, slow breathing, and increased heart rate, have also been observed. Gastrointestinal issues can include severe emesis (vomiting), and hepatotoxicity (liver damage) has been identified as a concern. While one survey of 10,000 self-reported Kratom users indicated a low incidence (less than 1%) of physical or psychological incidents requiring hospitalization or physician treatment compared to many common prescription drugs , this finding contrasts with increasing reports to poison control centers, suggesting a disparity in reported outcomes or reporting mechanisms.

7.3. Characterization of Withdrawal Syndrome

Kratom withdrawal occurs when the body, having adapted to the consistent presence of the substance, struggles to function normally without it. While the withdrawal symptoms are often reported as milder than those associated with traditional opioids , some reviews indicate that Kratom withdrawal itself can still be quite severe.

Common symptoms of Kratom withdrawal include hostility, aggression, emotional lability, rhinorrhea (wet nose), achy muscles and bones, and jerky movements of the limbs. A more comprehensive list of symptoms includes muscle aches, sweating, chills, nausea, vomiting, diarrhea, fatigue, insomnia, anxiety, depression, irritability, mood swings, intense cravings, difficulty concentrating, restlessness, headaches, dizziness, and sensitivity to light and sound.

The typical timeline for Kratom withdrawal begins with initial symptoms such as anxiety, restlessness, and irritability appearing within 6-12 hours after the last dose. Peak withdrawal symptoms, including muscle pain, sweating, nausea, insomnia, and strong cravings, usually occur between 24-48 hours. Symptoms generally begin to subside within 3-7 days, although psychological distress can persist for 1-2 weeks, with the potential for post-acute withdrawal syndrome (PAWS). Concurrent use of other substances, such as opioids, alcohol, or benzodiazepines, can exacerbate and worsen Kratom withdrawal symptoms. The contradiction between traditional accounts and some modern proponents suggesting milder withdrawal, versus increasing clinical reports of severe symptoms and the characterization of a distinct withdrawal syndrome, highlights a growing concern. This discrepancy indicates that while Kratom might be

relatively milder than some potent opioids, its withdrawal is far from benign, and its severity may be underestimated by users or traditional narratives, underscoring the need for more rigorous clinical research.

7.4. Concerns Regarding Adulteration and Contaminants

A significant medical concern, particularly prevalent in the unregulated market in the U.S., is the potential for adulteration of products sold as Kratom. The absence of comprehensive regulations means there are no adequate safeguards to protect consumers from tainted products. Some Kratom products have been found to contain contaminants not inherently associated with Kratom or its natural compounds. These contaminants can include dangerous substances such as salmonella, heavy metals, or even other controlled substances like fentanyl.

Furthermore, studies have revealed that some Kratom products contain notably elevated concentrations of 7-hydroxymitragynine compared to its natural presence in Kratom leaves. This is particularly alarming given that 7-OHMG is reported to be 14-22 times more potent than morphine. The unregulated market for Kratom, especially in Western countries, directly leads to such adulteration and contamination, which significantly amplifies the inherent risks of the substance itself. The fact that severe outcomes and fatalities are often linked to the presence of other drugs or contaminants, rather than Kratom alone , strongly suggests that the lack of regulatory oversight directly contributes to increased public health risks by allowing more potent or dangerous substances into the supply chain. This distinction from the risks of the pure plant is a major challenge for policy development.

7.5. Reported Fatalities

A very small number of deaths have been linked to Kratom products, and it is crucial to note that nearly all reported cases involved the presence of other drugs or contaminants. While no recorded deaths in the U.S. have been attributed solely to Kratom overdose, there have been instances of fatalities caused by overdosing on mixtures of Kratom and other controlled substances in the U.S., Norway, and Thailand. A particularly concerning example is “krypton,” a mixture of Kratom and tramadol, which has been linked to nine deaths in Sweden.

A Centers for Disease Control and Prevention (CDC) report analyzing 27,000 drug overdose deaths between 2016 and 2017 found that 152 patients tested positive for mitragynine, and it was deemed the cause of death in 91 of these cases, though often in contexts of poly-drug exposure. The FDA also reported 44 deaths linked to Kratom overdose in 2017. Additionally, concerns have been raised regarding pregnant mothers who used Kratom giving birth to newborns exhibiting signs of neonatal abstinence syndrome (NAS), similar to those observed with opioid exposure. These reports underscore the serious public health implications, particularly when Kratom is used in unregulated forms or in combination with other substances.

8. Key Individuals and Organizations in Kratom Research and Policy

The historical trajectory and contemporary understanding of Kratom have been shaped by the contributions of numerous individuals and the actions of various governmental and research organizations.

Botanists and Early Observers:

• Pieter Willem Korthals: A Dutch colonial botanist, Korthals is credited with formally describing Mitragyna speciosa in 1839, providing its initial scientific classification.
• George Darby Haviland: In 1859, Haviland provided the final name and classification for Mitragyna speciosa, solidifying its place in botanical taxonomy.

Chemists and Pharmacologists:

• Ellen Field: A medicinal chemist at the University of Edinburgh, Field achieved the significant milestone of first isolating mitragynine from Kratom leaves in 1921.
• G.A. Jeffrey: Leading a group at the University of Pittsburgh, Jeffrey was instrumental in characterizing mitragynine’s chemical structure using X-ray crystallography in 1964.
• Joseph Shellard and Arnold Beckett: Researchers at Chelsea College, London, who, from 1961 onwards, extensively examined the chemical structures of various alkaloids within Mitragyna species. Their work, alongside PhD students David Phillipson and Albert Tackie, significantly expanded the understanding of Kratom’s chemical components. Phillipson, in particular, isolated 16 alkaloids from M. speciosa and other Mitragyna species.
• Solomon Snyder and Candace Pert: These neuroscientists at Johns Hopkins University characterized the mu-opioid receptor for the first time in 1973, a discovery for which Snyder received the Lasker Award in 1978. Their work laid foundational knowledge crucial for understanding how Kratom’s alkaloids interact with the brain.

Modern Researchers:

• Christopher McCurdy, Ph.D.: A professor in the Department of Medicinal Chemistry at the University of Florida, Dr. McCurdy is an internationally recognized expert on Kratom. His research focuses on the design, synthesis, and development of drugs for pain and drug abuse, and he has presented on Kratom as a potential therapy for opioid dependence.
• Oliver Grundmann, Ph.D.: A clinical professor at the University of Florida, Dr. Grundmann’s research interests include natural products for central nervous system and gastrointestinal diseases, as well as the epidemiology of Kratom use.
• Jay McLaughlin, Ph.D.: A professor in the Department of Cellular and Systems Pharmacology at the University of Florida, Dr. McLaughlin conducts in vivo behavioral neuroscience and pharmacological tests to determine the effects of individual Kratom alkaloids on behavior.
• Abhisheak Sharma, Ph.D.: An assistant professor in the Department of Pharmaceutics at the University of Florida, Dr. Sharma’s research focuses on the pharmacokinetics of Kratom alkaloids.
• Albert Garcia-Romeu, David J. Cox, Kirsten E. Smith, Kelly E. Dunn, and Roland R. Griffiths: Researchers at Johns Hopkins University and the National Institute on Drug Abuse, who have contributed significantly to understanding Kratom user demographics, use patterns, and implications for the opioid epidemic through large-scale surveys.

Governmental and Research Organizations:

• U.S. Drug Enforcement Agency (DEA): Has formally listed Kratom as a “Drug and Chemical of Concern” and has been involved in attempts to classify it under the Controlled Substances Act.
• U.S. Food and Drug Administration (FDA): Has issued warnings to consumers about Kratom, classifying it as an “unapproved new dietary ingredient” and has repeatedly recommended its active compounds for Schedule I classification.
• Centers for Disease Control and Prevention (CDC): Has reported on Kratom-related calls to poison control centers and analyzed its presence in drug overdose deaths.
• National Institute on Drug Abuse (NIDA): Supports and conducts research to evaluate potential medicinal uses for Kratom and related chemical compounds.
• National Narcotics Agency (BNN, Indonesia): Has been a key player in advocating for a ban on Kratom in Indonesia, classifying it as a Class 1 narcotic.
• United Nations Office on Drugs and Crime (UNODC): Classified Kratom as a New Psychoactive Substance (NPS) in 2013.
• Expert Committee on Drug Dependence (ECDD) for the U.N. Commission on Narcotic Drugs: Has reviewed and rejected recommendations to schedule Kratom’s active compounds.

Advocacy Groups:

• American Kratom Association: A prominent advocacy group that has engaged in public education and lobbying efforts regarding Kratom’s legal status in the U.S..

These individuals and organizations collectively represent the diverse perspectives and efforts that have shaped the historical and contemporary understanding, as well as the complex regulatory environment, surrounding Mitragyna speciosa.

9. Conclusion

The history of Mitragyna speciosa, or Kratom, is a compelling narrative of a botanical substance deeply embedded in centuries of traditional use in Southeast Asia that has subsequently navigated a complex and often contentious path into the global arena. From its origins as a practical aid for laborers and a versatile traditional medicine, its journey reflects a profound ethnobotanical heritage, characterized by an empirical understanding of its dose-dependent stimulant and analgesic properties. Early scientific endeavors, beginning with the isolation of mitragynine in the 1920s, progressively revealed the intricate pharmacology of its alkaloids, particularly their unique interaction with opioid receptors that distinguishes them from classical opioids.

The global dissemination of Kratom, particularly its rapid surge in Western countries since the early 2000s, has been significantly influenced by contemporary public health challenges, most notably the opioid crisis. In this new context, Kratom has been perceived and utilized as a readily accessible alternative for pain management and opioid withdrawal, a role that contrasts sharply with its traditional integration into daily life and cultural rituals. This transition has occurred within an information void, as scientific understanding of its long-term effects and safety outside its native regions was largely absent, contributing to a public perception that often underestimated its pharmacological potency and potential risks.

The regulatory responses to Kratom have been as diverse and complex as its history. In its native lands, policies have evolved from early prohibitions, sometimes influenced by external factors such as opium control, to recent decriminalization efforts that acknowledge traditional cultural norms and the plant’s significant economic value to local communities. Conversely, in Western nations, the absence of federal oversight has led to a fragmented “patchwork” of state and local regulations, a situation exacerbated by ongoing scientific ambiguity, strong public advocacy, and substantial economic interests. This regulatory inconsistency underscores the challenges inherent in governing a substance with such a dual identity.

Moreover, the historical record, both traditional and modern, documents a spectrum of adverse effects, the recognition of dependence, and a defined withdrawal syndrome associated with Kratom use. A critical concern in the modern landscape is the amplified risk posed by an unregulated market, which has facilitated the adulteration of Kratom products with more potent compounds like concentrated 7-hydroxymitragynine or dangerous contaminants. These practices significantly escalate the potential for severe adverse outcomes, including fatalities, which are frequently linked to poly-substance exposure rather than Kratom alone.

In conclusion, the enduring legacy of Mitragyna speciosa is a testament to its multifaceted nature and its profound impact across cultures and time. The historical analysis reveals a plant of remarkable utility and cultural significance, yet one that, in its modern global context, presents complex challenges for public health and policy. Moving forward, comprehensive and rigorous scientific research remains paramount to fully elucidate its pharmacology, long-term health impacts, and potential therapeutic applications. Such evidence-based understanding is essential to inform balanced regulatory frameworks that can navigate the intricate interplay of traditional practices, economic realities, and public safety in the evolving global landscape of Kratom.